BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 26656522)

  • 21. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.
    Godtman RA; Carlsson S; Holmberg E; Stranne J; Hugosson J
    J Urol; 2016 May; 195(5):1390-1396. PubMed ID: 26678954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for prostate cancer.
    Postma R; Schröder FH
    Eur J Cancer; 2005 Apr; 41(6):825-33. PubMed ID: 15808952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [What has changed in the epidemiology and screening of prostate cancer?].
    Portela-Pereira P; Gómez-Veiga F
    Arch Esp Urol; 2015 Apr; 68(3):202-9. PubMed ID: 25948794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. States renewing attention to prostate cancer.
    Rossiter C
    NCSL Legisbrief; 2012 Sep; 20(36):1-2. PubMed ID: 23072022
    [No Abstract]   [Full Text] [Related]  

  • 27. Medical technologies for the diagnosis of prostate cancer.
    Fitzsimons NJ; Sun L; Moul JW
    Expert Rev Med Devices; 2007 Mar; 4(2):227-39. PubMed ID: 17359227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Mohler JL; Antonarakis ES; Armstrong AJ; D'Amico AV; Davis BJ; Dorff T; Eastham JA; Enke CA; Farrington TA; Higano CS; Horwitz EM; Hurwitz M; Ippolito JE; Kane CJ; Kuettel MR; Lang JM; McKenney J; Netto G; Penson DF; Plimack ER; Pow-Sang JM; Pugh TJ; Richey S; Roach M; Rosenfeld S; Schaeffer E; Shabsigh A; Small EJ; Spratt DE; Srinivas S; Tward J; Shead DA; Freedman-Cass DA
    J Natl Compr Canc Netw; 2019 May; 17(5):479-505. PubMed ID: 31085757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening.
    Ragsdale JW; Halstater B; Martinez-Bianchi V
    Prim Care; 2014 Jun; 41(2):355-70. PubMed ID: 24830612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Summaries for patients. Screening smarter, not harder, for prostate cancer.
    Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic performance of malignant prostatic cells detection in blood for early detection of prostate cancer: comparison to prostatic biopsy.
    Murray NP; Reyes E; Tapia P; Orellana N; Dueñas R; Fuentealba C; Badinez L
    Arch Esp Urol; 2011 Dec; 64(10):961-71. PubMed ID: 22228894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Screening for prostate cancer: time to put all the data on the table.
    Haines IE; Ablin RJ; Miklos GL
    BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
    [No Abstract]   [Full Text] [Related]  

  • 36. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer surveillance using registry data: Results and recommendations for the Lithuanian national prostate cancer early detection programme.
    Gondos A; Krilaviciute A; Smailyte G; Ulys A; Brenner H
    Eur J Cancer; 2015 Aug; 51(12):1630-7. PubMed ID: 26044924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for prostate cancer in asymptomatic men: clinical, legal, and ethical implications.
    Gerard MJ; Frank-Stromborg M
    Oncol Nurs Forum; 1998 Oct; 25(9):1561-9. PubMed ID: 9802052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.